Chardan Capital Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

REGENXBIO (NASDAQ:RGNX) had its price target dropped by investment analysts at Chardan Capital from $52.00 to $50.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target suggests a potential upside of 488.24% from the company’s current price.

Several other equities research analysts have also recently weighed in on RGNX. Leerink Partners increased their price target on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a research note on Thursday, January 29th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $27.80.

REGENXBIO Price Performance

RGNX opened at $8.50 on Tuesday. The stock’s 50 day simple moving average is $13.27 and its 200 day simple moving average is $11.41. The firm has a market cap of $430.27 million, a price-to-earnings ratio of -2.45 and a beta of 1.05. REGENXBIO has a 1 year low of $5.03 and a 1 year high of $16.19.

Hedge Funds Weigh In On REGENXBIO

A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. State of Alaska Department of Revenue purchased a new stake in shares of REGENXBIO in the 3rd quarter worth approximately $25,000. Aquatic Capital Management LLC bought a new stake in REGENXBIO in the third quarter worth $37,000. Jones Financial Companies Lllp grew its stake in shares of REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of REGENXBIO by 754.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of REGENXBIO in the 2nd quarter worth about $85,000. Institutional investors own 88.08% of the company’s stock.

Key REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Clear Street says RGNX still has over 300% upside despite the FDA pushback, arguing the longer‑term value of REGENXBIO’s AAV platforms and pipeline could dwarf the near‑term setback. Clear Street: RGNX upside
• Positive Sentiment: Morgan Stanley cut its price target from $25 to $18 but kept an “overweight” rating, signaling they still see roughly 110%+ upside from current levels and that the FDA decision may be a remediable regulatory/clinical issue rather than terminal for the franchise. Morgan Stanley coverage
• Positive Sentiment: Chardan Capital trimmed its target slightly (from $52 to $50) but maintained a “buy” rating, implying very large upside — Chardan’s stance supports investor hopes that pipeline value beyond RGX‑121 still justifies a high multiple. Chardan Capital coverage
• Negative Sentiment: The FDA declined to approve RGX‑121 for Hunter syndrome, a direct setback to REGENXBIO’s lead rare‑disease program and near‑term revenue/catalyst expectations; the decision spurred sharp share declines and increased regulatory uncertainty. FDA declines to approve RGX‑121
• Negative Sentiment: Multiple reports note the FDA rejection materially clouds the commercial path and prompted immediate downside pressure; investors should expect elevated volatility while REGENXBIO evaluates next steps (appeal, additional data, or new submission strategy). PharmaLetter: FDA rejection impact

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.